You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    PROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma

    SBC: APIE THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT The goal of this STTR proposal is to develop a novel anti-fibrotic agent suitable for oral administration which could be used to safely and effectively treat Systemic Sclerosis (SSc), or Systemic Scleroderma patients. SSc is one of the most disabling and lethal immune-mediated rheumatic disorders. SSc is a rare disease, affecting 40,000-150,000 people in the United States and conferring a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit

    SBC: SILICON CURES LLC            Topic: NINR

    PROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. PARCA (a digital tool) to improve Justice and Health

    SBC: Q2I, LLC            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Nearly 4.4 million individuals are on community supervision in the United States, with the majority (about 80%) being supervised under probation.1 Justice involved persons (JIPs) have a 474% increased lifetime experience with heroin, a 303% increased use of OxyContin in the last 12 months, and a 256% increased use in pain medication in the last 12 months, compared to the g ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A novel producer cell line for more efficient manufacturing of viral vector systems

    SBC: CLAIRIgene            Topic: 100

    ABSTRACT Significant advances in the specific targeting of delivery vectors and the increased therapeutic efficacy of such vectors for gene delivery have been made, stimulating major interest in the development and commercialization of therapeutic products focused on gene therapy indications. CLAIRIgene LLC focused on the development and optimization of various viral gene-to-cell transfer delivery ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Microfluidic technology platform as a continuous end-line process to inactivate pharmaceuticals

    SBC: NIGHTHAWK BIOSCIENCES, INC.            Topic: NCATS

    PROJECT SUMMARY To achieve the FDA’s required Sterility Assurance Level for use in humans, pharmaceutical products must undergo terminal sterilization or aseptic manufacturing. This can be accomplished using physical or chemical methods such as heat or formaldehyde for simple drug formulations; however, for pharmaceutical products that have more complex drug formulations or that contain biologic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia

    SBC: REGENNOVA, INC.            Topic: R

    Abstract: A Therapeutic Role for Apolipoprotein-E in the Germ Theory of ADP. gingivalis is the keystone bacteria of periodontal disease, the 6th most common infectious disease worldwide. Half of all Americans over the age of 30 and 70% of those over age 65 suffer some degree of P. gingivalis infection associated with gum disease. In a study of 6800 patients with gum disease that were followed for ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction

    SBC: NABGEN INC            Topic: NCATS

    Adeno-associated virus (AAV) vectors have been successfully employed in patients with rare neurological diseases. Recently, two AAV based gene therapy drugs have been approved by the FDA, Luxturna been valued at $850,000 with a one-time application for blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. AAV vector mediated gene therapy has shown to be a potentially huge market. Althou ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy

    SBC: Praetego Inc            Topic: NEI

    PROJECT SUMMARY Diabetic Retinopathy (DR) is a serious diabetic complication that is the leading cause of vision loss in working- age adults, affecting more than 7.5 million people in the USA. It causes more new cases of blindness than any other eye disease in people between the ages of 18 and 65. The anti-VEGF treatments can slow the progress of DR in many patients but are only used after signifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Leptin Receptor Agonist to Treat Sleep Disordered Breathing

    SBC: Arrevus, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS) are the most common types of sleep disordered breathing (SDB). OSA is highly prevalent in the United States, affecting 20-40% of the adult population and more than 50% of individuals with obesity. Approximately 20% of individuals with obesity develop OHS defined as daytime hypercapnia and hypoventilat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government